Por: Portland Press Herald World June 06, 2023
This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. AP Photo/Seth Wenig, File Merck is suing the U.S. over a law that will allow the government to negotiate prescription-drug prices with pharmaceutical companies — a reform aimed at cutting costs for elderly and disabled Medicare patients that the health-care giant says is “tantamount to extortion.” In a lawsuit filed Tuesday, Merck argues the negotiation... + full article
Politico USA Health June 06, 2023
Pharmaceutical giant Merck to block Medicare drug price negotiations, calling the program unconstitutional. The complaint, filed against the Department of Health and Human Services and the Centers for Medicare and Medicaid Services, argued that Medicare’s efforts to negotiate... + más
Merck sues U.S., calling Biden move to cut drug prices ‘extortion’ | Portland Press Herald
Merck sues over law empowering Medicare to negotiate with drug makers | The Boston Globe
Associated Press USA Business April 27, 2023
Merck beat first-quarter expectations and hiked its 2023 forecast even as sales plunged for its COVID-19 treatment and a strong dollar hurt revenue. Soaring sales of the drugmaker’s top seller, the cancer treatment Keytruda, helped counter those hits, a drop expected by... + más
Merck Tops Quarterly Profit Estimates but Sees Weaker 2023 Revenue on Lagevrio Sales Drop | MarketWatch
Merck has strong quarter even as COVID-19 treatment tumble | ABC News
ABC News USA Business April 27, 2023
Merck has strong quarter even as COVID-19 treatment tumble | Associated Press
Fox Business USA Business April 16, 2023
Check out what's clicking on FoxBusiness.com Merck & Co. is acquiring Prometheus Biosciences in a $10.8 billion deal. All the shares of Prometheus Biosciences will be acquired by a subsidiary of Merck for $200 per share.. promising immune disease treatments. The acquisition... + más
Merck in talks to acquire Prometheus Biosciences: report | Fox Business
Associated Press USA Health February 24, 2023
A European medical committee recommends rejection of Merck’s COVID-19 treatment, Lagevrio, casting fresh doubt on a pill that also stirs concern among U.S. regulators.A European Medicines Agency committee says marketing authorization for the antiviral pill for use in the... + más
Moderna, Merck announce progress in vaccine against skin cancer to significantly boost survival rate | ABC7
MarketWatch USA Business February 02, 2023
The company is expecting revenue to drop in 2023 amid a decline in sales of Lagevrio, its Covid-19 antiviral, and on Thursday set earnings guidance that was well below Wall Street expectations. Still, Merck Chief Financial Officer Caroline Litchfield said that the company’s... + más
Merck, Moderna detail potential skin cancer vaccine progress | WPLG Local 10
Merck, Moderna detail potential skin cancer vaccine progress | ABC News
WPLG Local 10 USA Health December 13, 2022
Moderna’s stock soared Tuesday after the COVID-19 vaccine maker detailed progress in developing a preventive shot for a deadly form of skin cancer.The company said a possible melanoma vaccine it is studying with pharmaceutical giant Merck fared well in a small study of... + más
Merck, Moderna detail potential skin cancer vaccine progress | Associated Press
About iurex | Privacy Policy | Disclaimer |